Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

AMTI - Applied Molecular Transport Inc.


Close
0.263
-0.044   -16.692%

Share volume: 0
Last Updated: Tue 26 Dec 2023 10:00:00 PM CET
Pharmaceutical Preparation Manufacturing : 2.72%

PREVIOUS CLOSE
CHG
CHG%

$0.31
-0.04
-14.30%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
24%
Profitability 25%
Dept financing 5%
Liquidity 35%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
-5.45%
1 Month
-9.09%
3 Months
11.11%
6 Months
-50.36%
1 Year
-84.92%
2 Year
-98.96%
Key data
Stock price
$0.26
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.21 - $2.09
52 WEEK CHANGE
-$0.84
MARKET CAP 
11.801 M
YIELD 
N/A
SHARES OUTSTANDING 
39.338 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$29,414
AVERAGE 30 VOLUME 
$75,599
Company detail
CEO: Tahir Mahmood
Region: US
Website: appliedmt.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Applied Molecular Transport Inc. engages in the design and development of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis.

Recent news